Bayer Aspirin Ads Highlight MI Prevention As Firm Pursues Label Change
This article was originally published in The Tan Sheet
The "Trust your heart to Bayer" aspirin ad campaign targets populations at risk for primary heart attack while the firm continues to pursue approval of professional labeling for that indication
You may also be interested in...
Bayer will submit additional data on subpopulation risks associated with aspirin therapy to support its citizen petition requesting amended professional labeling for primary prevention of myocardial infarction
Bayer may have a better shot of gaining FDA approval of expanded professional labeling for aspirin by pursuing an indication for prevention of non-fatal myocardial infarction. The firm got a negative advisory committee vote for prevention of all MIs at a Dec. 8 meeting
Aspirin therapy led to a statistically significant 32% reduction in first myocardial infarctions among over 55,000 subjects evaluated in a meta-analysis of five primary prevention studies conducted by Bayer Consumer Care